Himalaya almost built two brands instead of one — why it killed Ayurvedic Concepts

Sometime around 2001, a strange pattern started showing up in the call reports of Himalaya's medical representatives. When a rep walked into a doctor's clinic, instead of asking for the usual pen or paperweight — the standard promotional trinket reps left behind — doctors had started asking for something else: a bottle of anti-dandruff shampoo, or a face wash, or whatever personal care item happened to be in the rep's bag that week.

On paper, this made no sense. Himalaya's medical reps sold ethical pharmaceuticals — Liv.52, Cystone, Rumalaya — detailed strictly to doctors. The shampoo doctors were asking for belonged to a completely different brand: Ayurvedic Concepts, the personal care line Himalaya had deliberately launched under its own separate name in 1998–99. Two brands, two identities, two shelves. Doctors were not supposed to know the two were even connected.

But they did. And that field-level observation — not a boardroom brand audit, not a consultant's deck — is what pushed Himalaya toward one of the more instructive brand-architecture decisions in Indian pharma-FMCG history: retiring "Ayurvedic Concepts" entirely and folding every personal care product back under the Himalaya name.

Why Himalaya started with two brands in the first place

To understand why the merger mattered, you have to understand why Himalaya avoided it in the first place.

By the late 1990s, "Himalaya" was not a consumer brand. It was a prescription name. The company had been building pharmaceutical credibility since 1934, when it launched Serpina — recognised as the world's first natural antihypertensive drug, derived from a root a company founder had watched Burmese mahouts use to calm agitated elephants. In 1955, Himalaya launched Liv.52, a hepato-protective formulation that went on to become the only non-allopathic compound to consistently rank among India's top pharmaceutical brands. By the time personal care entered the picture, Himalaya's name carried decades of trust earned specifically from doctors — not consumers standing in front of a supermarket shelf.

That created a genuine dilemma. Putting a name built on prescription-pad trust onto a shampoo bottle, sitting next to Sunsilk and Dove in a supermarket aisle, was a real risk. Nobody at Himalaya knew for certain whether a name associated with pharmaceuticals could survive being commoditised on a retail shelf — or whether a failed personal care launch would drag pharmaceutical credibility down with it. So the company did what most cautious brand teams would do: it hedged. Personal care launched under its own name, Ayurvedic Concepts, insulated from the pharmaceutical business in case the experiment did not work. This is the same logic that shapes how pharma and FMCG marketing differ structurally — a prescription-earned name and a retail-shelf name are built through completely different trust mechanisms, and companies are usually careful about mixing the two.

The decision — and the numbers behind it

The rep reports were an early signal. But by the time Himalaya formally moved to consolidate everything under one name, the commercial case had become hard to ignore.

At the time of the rebrand, Ayurvedic Concepts was already generating meaningful revenue — reported figures put it at roughly ₹39 crore in sales, with the newly unified Himalaya brand rolling out across some 52 countries. Liv.52, meanwhile, was independently tracked as one of the largest pharmaceutical brands in the country by pharma market research firms of the period. Domestic demand for Ayurvedic and herbal products was climbing fast enough that industry estimates put the category at roughly a billion dollars.

Once management accepted that doctors, and by extension consumers, had already merged the two brands mentally, the strategic question flipped. The risk was no longer "what happens if we put Himalaya's name on a shampoo bottle." The risk was "what happens if we keep pretending these are two separate brands when nobody outside the company believes that anymore." Himalaya chose to stop fighting the merger the market had already made and lean into it instead.

The trust-transfer mechanic — why folding the brands worked

Consolidating under one name is a gamble unless the parent brand's trust is strong enough to carry weight across very different product categories. Himalaya's bet worked because of something specific: decades of endorsement from practising doctors — reported figures put the number at over 400,000 medical practitioners globally — had built a form of credibility that consumers could not manufacture through advertising alone.

Once personal care sat under the Himalaya name, that credibility transferred directly. A parent buying a Himalaya baby care product was leaning on the same trust a physician had already extended to Liv.52. A shopper picking up a face wash at a kirana store was, whether they realised it or not, drawing on the same brand promise that a gastroenterologist relied on when prescribing Liv.52 to a patient in a completely different country. One name meant the company only had to earn trust once — and then spend it everywhere.

This is the mechanism umbrella branding depends on: the parent name has to be doing real work as a signal, not just a label, or folding everything under it dilutes trust instead of transferring it.

There is a cognitive layer to this too. Consumer behaviour research on Himalaya's brand recognition has pointed to a familiarity effect — a name seen consistently across decades of pharmaceutical distribution becomes a shortcut consumers use to skip lengthy evaluation before a purchase. A shopper does not need to research a new personal care brand from scratch if the name on the bottle already feels familiar from somewhere else. Himalaya's decision to consolidate essentially cashed in that familiarity across an entirely new category, rather than starting the trust-building process over from zero under a new name.

The opposite lesson — what Crocin and Calpol chose instead

What makes the Himalaya decision worth studying is that it is not the obviously "correct" branding choice. It is one legitimate answer to a question that other pharma-adjacent companies have answered in exactly the opposite way.

Take the Crocin and Calpol paracetamol strategy run by GSK Consumer Healthcare. Rather than folding both brands into one name, GSK deliberately kept them separate — Calpol built entirely through paediatrician-facing medical detailing, Crocin built entirely through consumer-facing retail advertising. Same parent company, same underlying molecule, two completely separate brand identities, each protecting a different purchasing moment. That is a dual-brand pincer strategy: two names so that a competitor entering the category has to fight on two fronts at once.

Himalaya concluded the opposite was true for its business. Where GSK decided two brands could defend two different audiences better than one brand could, Himalaya decided that a single, sufficiently trusted name could carry an entire portfolio further than two disconnected identities ever could — especially once the market had already started merging the two brands in its own head regardless of what the company's org chart said.

What this means for your career

If you are heading into pharma marketing or brand strategy, the Himalaya case is a useful corrective to the assumption that umbrella branding is simply the "safe" or "default" choice. It is not safe. It is a bet that your parent brand's credibility is strong enough, and coherent enough across categories, to survive being stretched — and Himalaya only made that bet after the market itself supplied the evidence, in the unglamorous form of medical reps' call reports.

It is also a reminder that brand-architecture decisions are rarely made purely in a boardroom. The signal that mattered most here came from the field — from reps noticing an odd, repeated request that did not match the org chart. Paying attention to what customers, doctors, or patients are already doing with your brand, ahead of what your strategy documents say they should be doing, is often the more reliable source of insight.

Whether you end up defending two separate brand identities the way Crocin and Calpol did, or consolidating into one the way Himalaya did, the underlying question is the same: does keeping these identities separate protect something real, or is it just organisational inertia that the market has already stopped believing in?

Quick answers

Why did Himalaya rebrand Ayurvedic Concepts?

Himalaya's medical reps began noticing that doctors were asking for personal care items like shampoo instead of the usual pens and paperweights, which told management that doctors had already mentally merged Ayurvedic Concepts with Himalaya even though they were run as two separate brands. Rather than keep fighting that association, Himalaya folded personal care back under the Himalaya name to consolidate the trust it had already earned through decades of ethical pharmaceuticals.

What is Himalaya's umbrella branding strategy?

Himalaya runs every product line — ethical pharmaceuticals, personal care, baby care, and nutraceuticals — under one masterbrand name rather than separate sub-brands. The strategy works because the credibility earned from prescription products like Liv.52 transfers directly onto OTC and personal care items carrying the same name, converting clinical trust into consumer trust without having to build that trust twice.

Is Liv 52 owned by Himalaya?

Yes. Liv.52 is Himalaya's flagship hepato-protective formulation, launched in 1955, and remains the company's most prescribed pharmaceutical brand and the product most responsible for the medical credibility the rest of the Himalaya portfolio draws on.

If this was useful, the next piece worth reading is on how Crocin turned a generic molecule into a household brand — the inverse strategic bet, where two brands were kept deliberately separate instead of merged into one.